SK Biopharmaceuticals Co., Ltd. (KRX:326030)
South Korea
· Delayed Price · Currency is KRW 91,500
-900 (-0.97%)
Last updated: Jun 26, 2025
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
New Drugs | 547.60B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
New Drugs Growth | 54.30% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Service | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Service Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
Consolidated Adjustment | -594.66B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Consolidated Adjustment Growth | 27.97% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
United States | 667.82B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
United States Growth | 31.23% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
South Korea | 474.43B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
South Korea Growth | 52.69% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Consolidated Adjustment | -594.66B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Consolidated Adjustment Growth | 27.97% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Cayman Islands | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Netherlands | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Canada | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Japan | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Ireland | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|